{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:01:03Z","timestamp":1788433263499,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,3,8]],"date-time":"2012-03-08T00:00:00Z","timestamp":1331164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Plerixafor enhances the ability of filgrastim (FIL) to mobilize CD34+ cells but adds cost to the mobilization. We hypothesized that replacing weight\u2010based FIL with flat\u2010dose pegfilgrastim (PEG) in a validated cost\u2010based mobilization algorithm for patient\u2010adapted use of plerixafor would add convenience without increased cost.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> A single\u2010center retrospective analysis compared two consecutive cohorts undergoing FIL or PEG mobilization before autologous hematopoietic stem cell transplantation for multiple myeloma or lymphoma. FIL dose was 10\u2003\u00b5g\/kg\/day continuing until completion of collection and a 12\u2010mg flat dose of PEG. Peripheral blood CD34+ cells (PB\u2010CD34+) enumeration was performed on the fourth day after initiation of growth factor. Subjects surpassing a certain target\u2010specific threshold of PB\u2010CD34+ started apheresis immediately while subjects with lower PB\u2010CD34+ received plerixafor with apheresis starting on the fifth day.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Overall 68 of 74 in the FIL group and 52 of 57 patients in the PEG group met the mobilization target. Only one patient in each cohort required remobilization. Median PB\u2010CD34+ on Day 4 was significantly higher in patients in the PEG group (18.1\u2003\u00d7\u200310<jats:sup>6<\/jats:sup> vs. 28.7\u2003\u00d7\u200310<jats:sup>6<\/jats:sup> cells\/L, p\u2003=\u20030.01). Consequently, patients in the PEG group were less likely to require administration of plerixafor (67.5% vs. 45.6%, p\u2003=\u20030.01). Cohorts had near identical mean number of apheresis sessions and comparable CD34+ yield. The estimated cost associated with growth factor was higher in patients in the PEG group, but it was counterbalanced by lower cost associated with use of plerixafor.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Single administration of 12\u2003mg of PEG is associated with better CD34+ mobilization than FIL allowing for effective, convenient mobilization with less frequent use of plerixafor.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2012.03579.x","type":"journal-article","created":{"date-parts":[[2012,3,8]],"date-time":"2012-03-08T09:09:26Z","timestamp":1331197766000},"page":"2375-2381","source":"Crossref","is-referenced-by-count":29,"title":["Pegfilgrastim\u2010 versus filgrastim\u2010based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis"],"prefix":"10.1111","volume":"52","author":[{"given":"Luciano J.","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy R.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleen D.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Littleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie B.","family":"Shoptaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0408"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1547"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700867"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.369"},{"key":"e_1_2_7_11_2","first-page":"311","article-title":"Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma","volume":"4","author":"Moskowitz CH","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200061"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262080-00012"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(99)00112-5"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06054.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.10.018"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.12.268"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174946"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7209"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.130"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.028"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.170"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.78"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705848"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1663"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03136.x"},{"key":"e_1_2_7_27_2","article-title":"A risk\u2010based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor","author":"Abhyankar S","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-318220"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802636817"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00699.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705675"},{"key":"e_1_2_7_32_2","first-page":"225","article-title":"Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients","volume":"90","author":"Isidori A","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00911.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0675-5"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22597"},{"key":"e_1_2_7_36_2","doi-asserted-by":"crossref","unstructured":"HerbertK DemosthenousL WiesnerG LinkE WestermanDA CameN SeymourJF PrinceM.Plerixafor plus single\u2010dose pegfilgrastim for hematopoietic stem and progenitor cell mobilization: an efficient and safe regimen in good and poor mobilizer patients. ASH Annual Meeting Abstracts2010;116:2256.","DOI":"10.1182\/blood.V116.21.2256.2256"},{"key":"e_1_2_7_37_2","unstructured":"Amgen Inc.Neulasta (pegfilgrastim) Clinical Study Report: 20020112 [monograph on the internet].2005. [cited 2011 Oct 20]. Available from: URL:http:\/\/download.veritasmedicine.com\/REGFILES\/amgen\/20020112.pdf"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2012.03579.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2012.03579.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T16:39:08Z","timestamp":1697301548000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2012.03579.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,8]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1537-2995.2012.03579.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03579.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,8]]}}}